Stifel maintains Hold on Nyxoah stock, cites cash flow concerns

Oil prices are surged after Trump said an interim Iran peace deal is “over,” but for Nyxoah (NYXH) the key driver is worsening cash-burn risk: Stifel reiterates a Hold with a $3.00 target vs $1.68 shares, citing the company’s path to free-cash-flow breakeven as at least a couple of years and $85M FCF burned over the last 12 months. Stifel warns Nyxoah likely needs $200M+ additional capital to reach positive FCF, implying roughly $90M more for 2027 and potential further dilution, even after Nyxoah raised $110M for U.S. sleep apnea device expansion. Despite Q1 revenue of €6.4M (above estimates), Stifel cut its target multiple times on U.S. market and reimbursement challenges.

Analysis

This is less a fundamental rerate than a capitalization event: the equity is trading like a financing option on future adoption, not a clean claim on earnings power. When a company is still years from cash-flow breakeven and the next capital need is visible, even good operating prints mainly reduce near-term dilution risk rather than increase intrinsic value; that keeps the multiple capped and makes any rally vulnerable to supply from secondary paper.

The competitive implication is negative for smaller challengers in hypoglossal nerve stimulation. A weaker balance sheet raises execution risk for hospitals and physicians, so referral channels tend to favor the incumbent with steadier reimbursement support and a more credible long-duration service model. Over the next 1-3 months, the main catalyst is not revenue growth but financing structure: ATM usage, a new equity raise, or a convert would likely reset expectations again and pressure the stock even if sales continue to improve.

The contrarian view is that the market may already be pricing a near-worst-case dilution path, so the stock could bounce on any explicit runway extension or reimbursement win. The thesis is falsified if management can show a materially lower burn rate and a multi-quarter cash runway without another raise, or if U.S. adoption inflects enough to make 2027 funding needs materially smaller. Until then, this remains a balance-sheet trade more than a product-story trade.

Key Decisions for Investors

• Reduce/avoid fresh long exposure in NYXH for the next 1-3 months; the expected return is being diluted by financing overhang, while upside likely gets sold into any rally.
• If borrow/liquidity allow, short NYXH on strength or use a 3-6 month put spread; thesis is another financing event or guidance reset, with asymmetric downside if capital is raised at a discount.
• Pair trade: long INSP vs short NYXH only as a small, event-driven relative-value position; the spread should benefit if reimbursement uncertainty and balance-sheet concerns continue to favor the incumbent.
• Set an alert on any disclosed cash-runway extension or financing terms; if management can credibly push dilution out 12+ months, cover shorts quickly because the stock can re-rate sharply from depressed levels.
• Do not chase near-term revenue beats unless they are paired with lower cash burn; without that, operating upside mostly accrues to creditors and new investors rather than current equity holders.